An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

Data Suggest a Mechanism for ESA Resistance Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with an erythropoiesis stimulating ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Patients in the vadadustat groups were less likely to need ESA rescue therapy during the primary evaluation period, with 14.2% of patients requiring intervention vs. 27.7% in the MPG-EPO group.